Nozinan (Levomepromazine Hydrochloride)

Levomepromazine, the active ingredient in Nozinan, is a phenothiazine presented as a 25 mg tablet for oral use. It is employed in the management of severe agitation, psychotic disorders, and palliative care symptom control in adult patients. GNH USA supplies Nozinan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Nozinan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Levomepromazine is a low‑potency antipsychotic that acts on multiple neurotransmitter pathways, particularly in the context of severe psychiatric and palliative‑care conditions.

- Schizophrenia: helps reduce psychotic symptoms such as delusions and hallucinations. - Severe agitation or acute psychomotor excitement: calms patients who are highly restless. - Nausea and vomiting in palliative care: controls refractory nausea when other agents fail. - Painful muscle spasm and terminal restlessness (delirium) in end‑of‑life care: provides sedation and comfort. - Resistant hypertension? No, Lev... (truncated)

Levov…

...